High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: An evaluation of its use in 14 cases

British Journal of Dermatology

Volumn 140, Issue 5, 1999, Pages 865-874

  Harman, K E ^a   Black, M M ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Autoimmune bullous diseases; Bullous pemphigoid; Epidermolysis bullosa acquisita; Immunofluorescence; Intravenous immune globulin; Pemphigoid gestationis; Pemphigus vulgaris

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; IMMUNOGLOBULIN; MINOCYCLINE; NICOTINAMIDE; PREDNISOLONE; TETRACYCLINE;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; BULLOUS SKIN DISEASE; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; EPIDERMOLYSIS BULLOSA ACQUISITA; FEMALE; HUMAN; IMMUNOFLUORESCENCE; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; MALE; PEMPHIGOID; PEMPHIGUS VULGARIS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AUTOIMMUNE DISEASES; EPIDERMOLYSIS BULLOSA ACQUISITA; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; PEMPHIGOID, BULLOUS; RETROSPECTIVE STUDIES; SKIN DISEASES, VESICULOBULLOUS; TREATMENT OUTCOME;

EID: 0032966225     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.1999.02817.x     Document Type: Article

References (30)

1. Imbach P. Barandun S, d'Apuzzo V et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 36: 1228-31.
2. Godard W, Roujeau JC, Guillot B et al. Bullous pemphigoid and intravenous gammaglobulin. (Letter.) Ann Intern Med 1985; 103: 964-5.
3. Tappeiner G, Steiner A. High-dosage intravenous gamma globulin: therapeutic failure in pemphigus and pemphigoid. J Am Acad Dermatol 1989; 20: 684-5.
4. Humbert P, Derancourt C, Aubin F, Agache P. Effects of intravenous γ-globulin in pemphigus. (Letter.) J Am Acad Dermatol 1990: 22: 326.
5. Messer G, Sizmann N, Feucht H, Meurer M. High-dose intravenous immunoglobulins for immediate control of severe pemphigus vulgaris. Br J Dermatol 1995; 133: 1014-15.
6. Beckers RCY, Brand A, Vermeer BJ, Boom BW. Adjuvant high-dose intravenous gammaglobulin in the treatment of pemphigus and bullous pemphigoid: experience in six patients. Br J Dermatol 1995; 133: 289-93.
7. Bewley AP, Keefe M. Successful treatment of pemphigus vulgaris by pulsed intravenous immunoglobulin therapy. Br J Dermatol 1996; 135: 128-9.
8. Wever S, Zillikens D, Brocker E-B. Successful treatment of refractory mucosal lesions of pemphigus vulgaris using intravenous gammaglobulin as adjuvant therapy. Br J Dermatol 1996; 135: 852-66.
9. Colonna L, Cianchini G, Frezzolini A et al. Intravenous immunoglobulins for pemphigus vulgaris: adjuvant or first choice therapy? Br J Dermatol 1998; 138: 1102-3.
10. Meier F, Sönnichsen K, Schaumberg-Lever G et al. Epidermolysis bullosa acquisita: efficacy of high-dose intravenous immunoglobulins. J Am Acad Dermatol 1993; 29: 334-7.
11. Caldwell JB, Yancey KB, Engler RJM, James WD. Epidermolysis bullosa acquisita: efficacy of high-dose intravenous immunoglobulins. (Letter.) J Am Acad Dermatol 1994; 31: 827-8.
12. Mohr C, Sunderkotter C, Hildebrand A et al. Successful treatment of epidermolysis bullosa acquisita using intravenous immunoglobulins. Br J Dermatol 1995; 132: 824-6.
13. Kofler H, Wambacher-Gasser B, Topar G et al. Intravenous immunoglobulin treatment in therapy-resistant epidermolysis bullosa acquisita. J Am Acad Dermatol 1996; 34: 331-5.
14. Urcelay ML, McQueen A, Douglas WS. Cicatricial pemphigoid treated with intravenous immunoglobulin. Br J Dermatol 1997; 137: 467-84.
15. Meier F, Sönnichsen K, Schaumberg-Lever G et al. Epidermolysis bullosa acquisita: efficacy of high-dose intravenous immunoglobulins. (Letter.) J Am Acad Dermatol 1994; 31: 828.
16. Adoue D, Vilain C, Fontan B. Utilisation de très faibles doses d'immunoglobulines intraveineuses pour le traitement des pemphigoides bulleuses. Presse Med 1987; 16: 1625-7.
17. Harman KE, Whittam L, Wakeling S et al. Severe, refractory epidermolysis bullosa acquisita complicated by an oesophageal stricture responding to intravenous immune globulin. Br J Dermatol 1998 139: 1126-7.
18. Wakelin SH, Bhogal B, Black MM et al. Epidermolysis bullosa acquisita associated with epidermal-binding circulating antibodies. Br J Dermatol 1997; 136: 604-9.
19. Hern S, Harman KE, Bhogal B, Black MM. A severe and resistant case of pemphigoid gestationis treated with intravenous immunoglobulin and cyclosporin. Clin Exp Dermatol 1998; 23: 185-8.
20. Huber PJ. The behaviour of maximum likelihood estimates under non-standard conditions. In: Proceedings of the Fifth Berkeley Symposium, Mathematical Statistics and Probability. Berkeley, CA: University of California Press, 1967: 221-33.
21. Judd KP, Lever WF. Correlation of antibodies in skin and serum with disease severity in pemphigus. Arch Dermatol 1979; 115: 428-32.
22. Imbach P, Wagner HP, Berchtold W et al. Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet 1985; ii: 464-8.
23. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992; 326: 107-16.
24. Mouthon L, Kaveri SV, Spalter SH et al. Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin Exp Immunol 1996; 104 (Suppl. 1): 3-9.
25. Sams WM, Jordan RE. Correlation of pemphigoid and pemphigus antibody titres with activity of disease. Br J Dermatol 1971; 84: 7-13.
26. Judd KP, Mescon HM. Comparison of different epithelial substrates useful for indirect immunofluorescence testing of sera from patients with active pemphigus. J Invest Dermatol 1979; 72: 314-16.
27. Anhalt GJ, Labib RS, Voorhees JJ et al. Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 1982; 306: 1189-96.
28. Amagai M, Hashimoto T, Shimizu N et al. Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J Clin Invest 1994; 94: 59-67.
29. Blasczyk R, Westhoff U, Grosse-Wilde H. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet 1993; 341: 789-90.
30. Jolles S, Hughes J, Whittaker S. Dermatological uses of high-dose intravenous immunoglobulin. Arch Dermatol 1998; 134: 80-6.